DK1066276T3 - Fremgangsmåde til syntese af HIV protease inhibitor - Google Patents

Fremgangsmåde til syntese af HIV protease inhibitor

Info

Publication number
DK1066276T3
DK1066276T3 DK99910543T DK99910543T DK1066276T3 DK 1066276 T3 DK1066276 T3 DK 1066276T3 DK 99910543 T DK99910543 T DK 99910543T DK 99910543 T DK99910543 T DK 99910543T DK 1066276 T3 DK1066276 T3 DK 1066276T3
Authority
DK
Denmark
Prior art keywords
synthesis
protease inhibitor
hiv protease
hiv
inhibitor
Prior art date
Application number
DK99910543T
Other languages
English (en)
Inventor
John O'callaghan
Mark Stuart Robertson
Keith Rodgers
David D Vertex Pharm Deininger
Stephen Mcghie
Stephen John Rout
Hardev Singh
Roger Dennis Tung
Emile Pharm-Eco Labo Al-Farhan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1066276T3 publication Critical patent/DK1066276T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK99910543T 1998-03-20 1999-03-18 Fremgangsmåde til syntese af HIV protease inhibitor DK1066276T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (1)

Publication Number Publication Date
DK1066276T3 true DK1066276T3 (da) 2003-10-06

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910543T DK1066276T3 (da) 1998-03-20 1999-03-18 Fremgangsmåde til syntese af HIV protease inhibitor

Country Status (31)

Country Link
US (1) US6281367B1 (da)
EP (1) EP1066276B1 (da)
JP (1) JP3363439B2 (da)
KR (1) KR100555278B1 (da)
CN (1) CN1308319C (da)
AP (1) AP1226A (da)
AT (1) ATE242772T1 (da)
AU (1) AU751534B2 (da)
BR (1) BR9908970A (da)
CA (1) CA2324217C (da)
CZ (1) CZ299193B6 (da)
DE (1) DE69908761T2 (da)
DK (1) DK1066276T3 (da)
EA (1) EA003022B1 (da)
EE (1) EE04750B1 (da)
ES (1) ES2203090T3 (da)
GB (1) GB9805898D0 (da)
HR (1) HRP20000609B1 (da)
HU (1) HUP0105439A3 (da)
ID (1) ID26587A (da)
IL (1) IL138127A (da)
IS (1) IS2273B (da)
NO (1) NO317648B1 (da)
NZ (1) NZ506563A (da)
PL (1) PL201810B1 (da)
PT (1) PT1066276E (da)
RS (1) RS49954B (da)
SK (1) SK283939B6 (da)
TR (1) TR200002698T2 (da)
WO (1) WO1999048885A1 (da)
ZA (1) ZA200004482B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000045I2 (de) 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
ATE401298T1 (de) * 1999-12-23 2008-08-15 Ampac Fine Chemicals Llc Verbessertes verfahren zur herstellung von 2s,3s- n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
US7700645B2 (en) 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
JP4818124B2 (ja) * 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド (3R,3aS,6aR)−ヘキサヒドロフロ〔2,3−b〕フラン−3−イル(1S,1R)−3−〔〔(4−アミノフェニル)スルホニル〕(イソブチル)アミノ〕−1−ベンジル−2−ヒドロキシプロピルカルバマートの製造方法
KR101192859B1 (ko) * 2003-12-23 2012-10-19 얀센 알 앤드 디 아일랜드 (3r,3as,6ar)-헥사하이드로푸로〔2,3-b〕푸란-3-일(1s,2r)-3-〔〔(4-아미노페닐)설포닐〕(이소부틸)아미노〕-1-벤질-2-하이드록시프로필카바메이트의 제조방법
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
DE122007000045I2 (de) * 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease

Also Published As

Publication number Publication date
AP2000001911A0 (en) 2000-09-30
EP1066276A1 (en) 2001-01-10
ID26587A (id) 2001-01-18
TR200002698T2 (tr) 2000-12-21
HRP20000609B1 (en) 2006-05-31
NO20004664D0 (no) 2000-09-19
EA003022B1 (ru) 2002-12-26
DE69908761T2 (de) 2004-02-19
DE69908761D1 (de) 2003-07-17
EP1066276B1 (en) 2003-06-11
AP1226A (en) 2003-11-21
JP2002507609A (ja) 2002-03-12
SK283939B6 (sk) 2004-05-04
CA2324217C (en) 2008-02-19
HK1032047A1 (en) 2001-07-06
ATE242772T1 (de) 2003-06-15
AU2947599A (en) 1999-10-18
BR9908970A (pt) 2000-11-28
YU55900A (sh) 2003-02-28
HRP20000609A2 (en) 2001-04-30
NZ506563A (en) 2003-05-30
PL342602A1 (en) 2001-06-18
PT1066276E (pt) 2003-10-31
EA200000859A1 (ru) 2001-04-23
KR20010042022A (ko) 2001-05-25
IS5605A (is) 2000-08-29
CZ299193B6 (cs) 2008-05-14
CN1308319C (zh) 2007-04-04
HUP0105439A2 (en) 2002-06-29
ZA200004482B (en) 2001-11-28
US6281367B1 (en) 2001-08-28
GB9805898D0 (en) 1998-05-13
SK13732000A3 (sk) 2001-08-06
KR100555278B1 (ko) 2006-03-03
WO1999048885A1 (en) 1999-09-30
AU751534B2 (en) 2002-08-22
RS49954B (sr) 2008-09-29
CN1293668A (zh) 2001-05-02
NO20004664L (no) 2000-09-19
JP3363439B2 (ja) 2003-01-08
EE04750B1 (et) 2006-12-15
IS2273B (is) 2007-07-15
CZ20003457A3 (cs) 2001-04-11
NO317648B1 (no) 2004-11-29
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
PL201810B1 (pl) 2009-05-29
EE200000568A (et) 2002-02-15
IL138127A (en) 2003-10-31
CA2324217A1 (en) 1999-09-30
ES2203090T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
EE200000798A (et) HIV proteaasi inhibiitori bisulfaatsool
IS4928A (is) Fosfín tengdir tálmar af grindar málmpróteösum
DK1064298T3 (da) Inhibitorer af caspaser
DK1016836T3 (da) Fremgangsmåde til tilvejebringelse af köling
DK1686113T3 (da) Inhibitorer af aspartylprotease
DK1086076T3 (da) Sulfonamidinhibitorer af aspartylprotease
EE200000386A (et) Aspartüülproteaasi inhibiitorite eelravimid
DK1105413T3 (da) Hepatitis C-inhibitor-tripeptider
ATE264339T1 (de) Serine protease inhibitoren
NO990548L (no) Inhibitorer for cystein-protease
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1294659T3 (da) Fremgangsmåde til isolering af katamin
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
IS2273B (is) Aðferð fyrir nýsmíðina á HIV próteasa lötum
DK1102747T3 (da) Krystalformer af osenetant
DK1286940T3 (da) Fremgangsmåde til fluormethylering af alkoholer
DK1023292T3 (da) Fremgangsmåde til syntese af chlorpurinintermediater
DK1311679T3 (da) Fremgangsmåde til inhibering af IL-22-induceret PAP1
DK1070999T3 (da) Fremgangsmåde til overfladeformning af urværksdele
DK1361216T3 (da) Fremgangsmåde til fremstilling af en HIV-proteaseinhibitor
EE9900416A (et) HIV-proteaasi inhibiitorid
EP1195163A4 (en) Serine protease inhibitors
DK1319049T3 (da) Grunding af stål
BR1100661A (pt) Compostos inibidores de protease retroviral